Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Theory-based dyadic co-learning intervention to enhance family resilience in men with prostate cancer and their spouses in Taiwan: protocol for a randomised controlled trial.

BMJ open·2026
Same author

Multiplex biomarker detection platform based on zinc protoporphyrin-modified gold electrodes: Application potential for early diagnosis and postoperative monitoring of prostate cancer.

Biosensors & bioelectronics·2026
Same author

Identification of Novel Genetic Risk Variants Associated With Early-Onset Ischemic Stroke in Taiwan.

Neurology·2026
Same author

Distinct subtypes of kidney transplant-associated urothelial carcinomas harboring BK polyomavirus integration and aristolochic acid mutational signatures.

Biomedical journal·2026
Same author

The impact of caregivers' illness perception and emotional expression on medication adherence in patients with schizophrenia.

BMC psychology·2026
Same author

Overweight status predicts improved overall survival after radical nephroureterectomy for upper tract urothelial carcinoma.

The Canadian journal of urology·2026

Related Experiment Video

Updated: Jun 19, 2026

Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
08:19

Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing

Published on: June 1, 2012

14.5K

Rocket-Like Microneedle Patch for Sustained Hormone Therapy in Prostate Cancer.

Ying-Tzu Chen1,2, Kuan-Ta Chen3, Kai-Jie Yu4,5

  • 1Department of Neurosurgery, Chang Gung Memorial Hospital, Linkou Branch, Taoyuan 33305, Taiwan.

ACS Biomaterials Science & Engineering
|July 18, 2025
PubMed
Summary

A novel rocket-like microneedle patch delivers sustained hormone therapy for prostate cancer (PCa). This painless, self-administered patch improves treatment compliance and efficacy, offering a promising new approach for PCa management.

Keywords:
hormone therapymicroneedle patch (MNP)prostate cancer (PCa)sustained drug releasezeolitic imidazolate framework-8 (ZIF-8)

More Related Videos

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

25.4K
Author Spotlight: Innovative Microneedle-Based Strategies for Enhanced Exosome Delivery and Stability
07:41

Author Spotlight: Innovative Microneedle-Based Strategies for Enhanced Exosome Delivery and Stability

Published on: July 12, 2024

2.6K

Related Experiment Videos

Last Updated: Jun 19, 2026

Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing
08:19

Hollow Microneedle-based Sensor for Multiplexed Transdermal Electrochemical Sensing

Published on: June 1, 2012

14.5K
Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia
08:38

Renal Capsule Xenografting and Subcutaneous Pellet Implantation for the Evaluation of Prostate Carcinogenesis and Benign Prostatic Hyperplasia

Published on: August 28, 2013

25.4K
Author Spotlight: Innovative Microneedle-Based Strategies for Enhanced Exosome Delivery and Stability
07:41

Author Spotlight: Innovative Microneedle-Based Strategies for Enhanced Exosome Delivery and Stability

Published on: July 12, 2024

2.6K

Area of Science:

  • Biomedical Engineering
  • Oncology
  • Materials Science

Background:

  • Prostate cancer (PCa) presents a significant global health burden, driving the need for innovative therapeutic strategies.
  • Current hormone therapies for PCa face challenges including poor patient compliance and treatment-associated discomfort.

Purpose of the Study:

  • To develop and evaluate a dual-layer rocket-like microneedle patch (RLMNP) for sustained hormone therapy in prostate cancer.
  • To assess the efficacy of RLMNP in blocking androgen receptor signaling and suppressing androgen synthesis.

Main Methods:

  • Fabrication of a dual-layer RLMNP integrating a rapid-release layer (ZIF-8/bicalutamide) and a sustained-release layer (Alg-Tyr hydrogel/goserelin).
  • Evaluation of RLMNP mechanical properties, skin penetration, and drug release kinetics.
  • In vivo assessment of RLMNP efficacy in reducing tumor volume and extending survival in prostate cancer models.

Main Results:

  • RLMNP demonstrated robust mechanical properties, efficient skin penetration, and controlled dual drug release.
  • In vivo studies showed significant reduction in tumor volume and extended survival from 34 to 46 days.
  • The RLMNP system effectively mitigated side effects associated with conventional hormone therapies.

Conclusions:

  • RLMNP offers a promising, painless, and self-administered platform for sustained prostate cancer hormone therapy.
  • This dual-action microneedle patch improves therapeutic outcomes and patient compliance.
  • The developed RLMNP technology paves the way for broader applications of microneedle-based transdermal drug delivery in oncology.